Tetrahedron Letters,Vo1.30,No.33,pp 4379-4382,1989 0040-4039/89 \$3.00 + .OO Printed in Great Britain

A HIGHLY EFFICIENT SYNTHESIS OF NATURAL PGE<sub>2</sub> AND 5,6-DIHYDRO PGE<sub>3</sub> VIA TWO-COMPONENT COUPLING PROCESS

Sentaro Okamoto,' Yuichi Kobayashi, and Fumie Sate\* Department of Chemical Engineering, Tokyo Institute of Technology Meguro, Tokyo 152, Japan

 $Summany:$  A highly practical synthesis of natural  $PGE<sub>3</sub>$  and  $5.6$ -dihydro  $PGE<sub>3</sub>$ via two-component coupling process is described.

One of the most reliable and attractive methods for synthesis of natural prostaglandins (PGs) and their analogues is the two component coupling process via conjugate addition, which is classified into two possible routes shown in eq 1 and 2.<sup>2</sup> Recently we have developed highly



practical methods to prepare all chiral key intermediates used in eq 1 and 2, i. e. enones 1 and 2,<sup>3</sup> and the  $\omega$  side-chain unit 3.<sup>4</sup> Thus, the two component coupling process has now become industrially viable. $^5$  Continued from our recent synthesis of PGE<sub>1</sub> and PGE<sub>2</sub> by using eq 1 and/or eq 2,<sup>3</sup> we have selected PGE<sub>3</sub> and 5,6-dihydro PGE<sub>3</sub> as next targets. PGE<sub>3</sub> is distinguished from PGE<sub>2</sub> by an additional cis-double bond between  $C-17$  and  $C-18$ . The presence of this double bond seems to make its synthesis more difficult.<sup>6</sup>



5,6-Dihdro PGE<sub>3</sub> was isolated from ram seminal vesicles recently and was shown to be 14 **times less** active uterine stimulant than PGB,, while it retains a similar potency in inhibition of platelet aggregation to that of PGE<sub>1</sub>.<sup>7</sup> Because of this unique physiological activity, an efficient supply of 5,6-dihydro PGE<sub>3</sub> by chemical synthesis is desirable for its clinical investigations.

, We herein report synthesis of PGE<sub>3</sub> and 5,6-dihydro PGE<sub>3</sub> according to eq 2. The preparation of the common w side-chain unit 4 was carried out according to the procedure shown in Scheme I. Starting with (E)-3-trimethylsilyl-2 propenal  $(5)$ , the compound 6 was prepared in 96% yield by propargylation followed by protection of the hydroxyl\_group\_as\_the\_ethoxyethyl\_ether. $^8$ Reaction of lithium anion of 6 with EtBr afforded 7 in 70% yield. Hydrolysis of 7 with 3N HCl in MeOH-H<sub>2</sub>O and cis-reduction using Lindlar catalyst furnished 8 in 86% yield. The kinetic resolution of 8 by the Sharpless procedure using TBHP, Ti(O-i-Pr),, and L-(+)-DIPT gave (R)-8 (>99% ee) in 48% yield and 9 (>99% ee) in 44% yield.<sup>9,10</sup> After separation of (R)-8 and 9 by chromatography on silica gel, 9 was converted into 4 in 73% yield by silylation, followed by' the reaction with  $Bu<sub>3</sub>SnLi. Similarly, (R)-8 was$ converted into 4 in 53% overall yield via the epoxy alcohol 10 by epoxidation followed by inversion of the hydroxyl group using the Mitsunobu procedure. 4a



 $^a$ (a) BrCH<sub>2</sub>CECH. Zn powder, TiCl<sub>4</sub> (cat.). THF: (b) H<sub>2</sub>C=CHOEt, PPTS (cat.). CH<sub>2</sub>Cl<sub>2</sub>: (c) n-BuLi, EtBr, THF; (d) PPTS (cat.), MeOH; (e) H<sub>2</sub> (1 atm), Lindlar catalyst. **MeOH;** (f) L-(+)-DIPT, Ti(O-i-Pr)<sub>4</sub>, TBHP, CH<sub>2</sub>Cl<sub>2</sub>; (g) D-(-)-DIPT, Ti(O-i-Pr)<sub>4</sub>, TBHP, CH<sub>2</sub>Cl<sub>2</sub>: (h) EtO<sub>2</sub>CN=NCO<sub>2</sub>Et. p-O<sub>2</sub>N-PhCO<sub>2</sub>H. PPh<sub>3</sub>. THF; (i) 1N NaOH. THF-H<sub>2</sub>O; (j) t-BuMe<sub>2</sub>SiCl. imidazole. DMF; (k) n-Bu<sub>3</sub>SnH. LDA. THF.

With the  $\omega$  side-chain unit 4 in hand we carried out the synthesis of  $(-)$ -PGE<sub>3</sub> and 5,6-dihydro PGE<sub>3</sub> (Scheme II). The enone 12<sup>11</sup> ([a]<sub>D</sub><sup>25</sup> -46.8<sup>o</sup> (c) 1.03, CHCl<sub>3</sub>)) was prepared in 88% yield by the reaction of the enone 11<sup>3,12</sup> (1.1 eguiv) with the higher ordered cyano mixed cuprate prepared from

the vinyllithium derived from **4** and (2-thienyl)Cu(CN)Li<sup>13</sup> (1.2 equiv) (THF, -78  $\degree$ C to 0  $\degree$ C, 1 h). The enone 12 reacted with the higher ordered cuprate derived from (Z)-LiCH=CH(CH<sub>2</sub>)<sub>4</sub>OEE (1.3 equiv, EE = ethoxy ethyl) and (2-thienyl)Cu(CN)Li (1.5 equiv) in THF-Et<sub>2</sub>O-pentane at -78 <sup>O</sup>C to 0 <sup>O</sup>C for 1h to give the  $1,4$ -addition product 13 in 80% yield. The compound 13 was converted into (-)-PGE<sub>2</sub> (mp 84.5-85.5 °C (recrystallized from [a]<sub>n</sub><sup>24</sup> -50.0<sup>o</sup> (c 1.08, THF), lit.<sup>6a</sup> [a]<sub>n</sub><sup>24</sup> -48.9<sup>o</sup> (c 1.2, THF)) by the following sequence: (1) PPTS (cat.), i-PrOH-Et<sub>2</sub>O, room temp., 5 h, 86% yield; (2) Jones reagent (2.6 equiv), acetone-Et<sub>2</sub>O, 0 °C, 30 min, 79% yield;(3)  $aq$ . HF, CH<sub>3</sub>CN, room temp., 40 min, 78% yield. The spectroscopic data of (-)-PGE<sub>3</sub> thus obtained were in good agreement with the reported one.<sup>14</sup> In a similar way, 5,6-dihydro PGE<sub>3</sub> ([ $\alpha$ ] $_{\alpha}$ <sup>25</sup> -50.6<sup>C</sup> (c 0.83, THF), mp 60.0-61.0 (recrystallized from hexane-Et<sub>2</sub>O)) was obtained in 54% overall yield from **12** and the higher ordered cuprate derived from ClMg(CH<sub>2</sub>)<sub>6</sub>OEE and (2-thienyl)Cu(CN)Li. The spectral data of 5,6-dihydro PGE<sub>2</sub> thus synthesized supported the structure. <sup>15</sup>



<sup>a</sup>(a) n-BuLi then (2-Thienyl)Cu(CN)Li, THF, -78 °C; (b) (Z)-ICH=CH(CH<sub>2</sub>)<sub>A</sub>OEE, t-BuLi, Et<sub>2</sub>O then (2-Thienyl)Cu(CN)Li, THF, -78 °C to 0 °C; (c) ClMg(CH<sub>2</sub>)<sub>6</sub>OEE, (2-Thienyl)Cu-(CN)Li. THF. -78 °C to 0 °C; (d) PPTS (cat.). i-PrOH-Et<sub>2</sub>0. room temp., 4-5 h; (e) Jones reagent, acetone-Et<sub>2</sub>O, O °C, 20-30 min; (f) aq. HF, CH<sub>3</sub>CN, room temp., 40 min.

## References and Footnotes

(1) Fellow of the Japan Society for the Promotion of Science for Japanese Junior Scientists, **1988-1990. (2) R.** Noyori, M. Suzuki, Angew. Chem., Int.

**Ed.** Engl., 23, 847(1984) and references cited therein. (3) S. Okamoto, Y. Kobayashi, H. Kato, K. Hori, T. Takahashi, J. Tsuji, F. Sato, J. Org. Chem., **53, 5590(1988).** (4) (a) S. Okamoto, T. Shimazaki, Y. Kobayashi, F. Sato, Tetrahedron Lett., 28, **2033(1987).** (b) Y. Kitano, T. Matsumoto, S. Okamoto, T. Shimazaki, Y. Kobayashi, F. Sato, Chem. Lett., l523(l987). (c) Y. Kitano, T. Matsumoto, T. Wakasa, S. Okamoto, T. Shimazaki, Y. Kobayashi, F. SatO, K. Miyaji, K. Arai, Tetrahedron-Lett., 28, 6351(1987). (5) The intermediates **1, 2, and 3** are now commercially available from Nissan Chemical Industries, Ltd. (Japan). (6) Total synthesis of  $(-)$ -PGE<sub>3</sub>: (a) E. J. Corey, H. Shirahama, H. Yamamoto, S. Terashima, A. Venkateswarlu, T. K. Schaaf, J. Am. Chem. Soc., 93, 1490(1971). See also: (b) J. Fried, C. H. Lin, C. J. Sih, P. Dalven, G. F. Cooper, J. Am. Chem. Soc., 94, 4342(1972). Synthesis of dl-PGE<sub>3</sub> methyl ester: (c) U. Axen, J. L. Thompson, J. E. Pike, J. Chem. Soc., Chem. Commun., 602(1970). (7) (a) N. Samel, I. Järving, M. Lõhmus, A. Lopp, G. Kobzar, V. Sadovskaya, T. Välimäe, U. Lille, PROSTAGLANDINS, 33, 137(1987). (b) E. H. Oliw, H. Sprecher, M. Hamberg, J. Biol. **Chem., 261,**  2675(1986), in this paper this PG was named as  $17,18$ -dehydro PGE<sub>1</sub>. (8) T. Shimazaki, Y. Kobayashi, F. Sate, Chem. Lett., 1785(1988). (9) Optical purities of  $(R)$ -8 and 9 were determined by  $1_H$  NMR analysis of the corresponding MTPA esters. (10) Y. Kitano, T. Matsumoto, F. Sato, J. Chem. sot., Chem. Commun., **1323(1986). Y.** Kitano, T. Matsumoto, F. Sato, Tetrahedron, 44, 4073(1988). **(11) 12:** 'H NMR (CDC13, 200 **MHz) 6 0.01** and **0.04 (25, 12H), 0.86** and **0.88 (Zs, 18H), 0.93 (t, J = 7.6 Hz, 3H), 1.92-2.10 tm, 2H), 2.11-2.35** (m, 2H), 2.32 (ad, J = 7.0, 17.8 Hz, lH), 2.62 (da, J = 17.8, 6.4 Hz, **IH), 3.21-3.33** (m, IH), 4.01-4.21 (m, 2H), 5.20 (ad, J = 1.7, 2.8 Hz, lH), 5.21-5.56 (m, 2H), 5.49 (ad, J = 7.4, 15.2 Hz, IH), 5.63 (dd, J = **15.2,**  4.6 Hz, 1H), 6.08 (dd, J = 2.8, 1.4 Hz, 1H). <sup>13</sup>C NMR (CDC1<sub>3</sub>, 200 MHz)  $6 - 4.9$ , **-4.7, 14.0, 17.8, 18.0, 20.5, 25.6, 25.7, 36.2, 46.8, 54.4, 72.5, 72.9, 119.3, 124.8, 127.7, 133.7, 137.4, 147.0, 203.6. (12)** The enone 11 is also commercially available from Nissan Chemical Industries, Ltd., see note 5. (13) B. H. Lipshutz, M. Koerner, D. A. Parker, Tetrahedron Lett., 28, 945(1987). B. H. Lipshutz, Synthesis, 325(1987). (14) B. Samuelson, J. Am. Chem. Soc., 85, 1878(1963). (15) 5,6-Dihydro PGE<sub>3</sub>: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz) 6 0.96 (t, J = 7.5 Hz, 3H), 1.13-1.75 **(m,** lOH), 1.90-2.49 (m, 7H), 2.31 (t, J = 7.3 Hz, 2H), 2.72 (dd, J = 17.8, 7.1 Hz, 1H), 4.04 (q, J = 8.7 Hz, 1H), 4.17 (q,  $J = 6.4$  Hz, 1H), 4.20-5.40 (br s, 3H), 5.30 (dt,  $J = 10.8$ , 7.5 Hz, 1H), 5.53 (m, 1H), 5.58 (dd, J = 8.1, 15.2 Hz, 1H), 5.69 (dd, J = 15.2, 6.4 Hz, **IH). 13C NMR (CDC13, 200** MHz) 6 14.0, 20.5, 24.3, 26.2, 27.3, 28.5, 29.0, 33.8, 34.7, 45.6, 54.2, 54.6, 71.7, 72.5, 123.5, 132.6, 135.0, 135.9, **179.1, 215.6.** 

(Received in Japan 12 April 1989)